Plenary Session 15
3月28日［日］08:00-09:30
|
| |
| |
Recent advance of cardiovascular regeneration research
|
|
|
| |
| |
|
|
| |
本邦における循環器領域の再生医学の基礎研究は著しく発展し、臨床応用への加速に大きな貢献をしている。ES細胞iPS細胞からの心筋細胞への分化誘導系はほぼ確立し、心室筋心房筋への選択的分化も可能になった。また、心筋細胞を試験管内で成熟化する技術も徐々に開発され、創薬への応用も期待されている。さらに様々な遺伝性心疾患に対して疾患モデルiPS細胞が作出され、病態解明や創薬ターゲットの解析に使用されるに至っている。また、再生医療の臨床応用を見据えた大動物モデルでの研究や、組織工学的手法を用いたミニ心筋組織の開発も行われている。臨床応用を見据えた大量製造法の開発や、心筋細胞の純化精製法に関する研究も大きな成果を上げている。線維芽細胞等に心筋特異的遺伝子を導入することにより、心筋様細胞を作出するダイレクトリプログラミング法に関しても技術開発が進み、作出効率も向上している。本プレナリーセッションではこれらの心筋再生医療を牽引する基盤技術の開発にフォーカスをあて、近未来の心筋再生医療の将来像を見通すことを目指す。
Basic research on regenerative medicine in the cardiovascular field in Japan has made remarkable progress and has made a great contribution to its acceleration to clinical application. The differentiation induction system from ES and iPS cells to cardiomyocytes has been established, and selective differentiation into ventricular muscles and atrial muscles has become possible. In addition, a technique for maturing cardiomyocytes in vitro has been gradually developed, and is expected to be applied to drug discovery. Furthermore, disease model iPS cells have been produced for various hereditary heart diseases and have been used for elucidation of pathological conditions and analysis of drug targets. In addition, research on large animal models with a view to clinical applications of regenerative medicine and development of mini myocardial tissue using tissue engineering techniques are also being carried out. The development of mass production methods with a view to clinical application and research on purification methods for cardiomyocytes have also produced great results. By introducing combination of myocardium-specific genes into fibroblasts or other type of cells, technological development has progressed and the efficiency of production has also improved with respect to the direct reprogramming method for producing myocardial-like cells. In this plenary session, we will focus on the development of fundamental technologies that will drive these myocardial regenerative medicine, and aim to see the future image of myocardial regenerative medicine in the near future.
|
|
|
| |
| |
|
|
| |
| |
 |
|
Keiichi Fukuda
Department of Cardiology, Keio University School of Medicine, Tokyo
|
|
 |
|
Charles Murry
Labratory Medicine and Pathology, University of Washington, Seattle, USA
|
|
|
| |
| |
| |
| |
|
|
| |
| |
|
|
Charles Murry
Labratory Medicine and Pathology, University of Washington, Seattle, USA
|
|
 |
|
Shugo Tohyama
Department of Cardiology, Keio University School of Medicine, Tokyo
|
|
|
| |
| |
 |
|
Yoshinori Yoshida
Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto
|
|
 |
|
Masaki Ieda
Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba
|
|
|
| |
| |
|
|